Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
To prevent toxicity of free
2021-11-18
To prevent toxicity of free hemoglobin as well as its degradation metabolites heme and free iron, several scavenger proteins and degradation enzymes protect the body. Haptoglobin (Hp) is the most well described hemoglobin scavenging protein that binds free hemoglobin and transports it to macrophages
-
In order to better manage
2021-11-18
In order to better manage HBV infection and related liver diseases, it is critical to develop new antiviral strategies to increase the rate of functional or complete cure of HBV infection (HBsAg loss and cccDNA elimination), achieving more than viral suppression (Zeisel et al., 2015). As a result, m
-
br Materials and methods br Results Our
2021-11-18
Materials and methods Results Our data indicated that 1,8-cineol leads to a noticeable but not significant (p = 0.07) 45% decreased phosphorylation of GSK-3α/β at Ser-9/21. Phosphorylation of GSK-3α/β at Tyr-279/216 was not affected (Fig. 1A/B). To ensure, that the decreased phosphorylation of
-
Our aim was to gain insight into mechanisms that underlie
2021-11-18
Our aim was to gain insight into mechanisms that underlie the contribution of thrombospondin-1 (TSP1) to progression of CKD. TSP1 is the most-studied member of the thrombospondin family of matricellular proteins. Previous studies have demonstrated that pharmacological suppression or genetic depletio
-
Starting from commercially available dioxaspiro
2021-11-17
Starting from commercially available 1,4-dioxaspiro[4.5]decan-8-ol, was prepared by the synthetic sequence illustrated in . Aromatic nucleophilic substitution of 1,4-dioxaspiro[4.5]decan-8-ol, followed by an Chk1 and MK2 Inhibitors set catalyzed deprotection efficiently gave . A - enriched mixture
-
br Clinical development of anti
2021-11-17
Clinical development of anti-NASH drug therapies The current understanding of NASH pathogenesis has led to broad efforts to target several features of the disease, alone or in combination, even in the absence of liver-guided therapies. Therefore, drug development in NASH is a rapidly changing fie
-
This study does have important limitations
2021-11-17
This study does have important limitations to consider. The utilization of a recombinant gp120 monomer (at a single concentration of 100 ng/ml) instead of live virus particles may limit the validity of our results. Moreover, extrapolation of an in vitro cell culture model to animals or humans cannot
-
Molecular properties as well as metabolic
2021-11-17
Molecular properties as well as metabolic stability in rat and human liver microsomes for the most active nitro (), nitrile (), methylsulfone (), and sulfonamides () analogues were measured (). All these derivatives possessed excellent membrane permeability as measured in the Pampa assay and further
-
br Treatment KD is currently the treatment of choice for
2021-11-17
Treatment KD is currently the treatment of choice for GLUT1-DS. It is a high-fat, carbohydrate-restricted diet that mimics the metabolic state of fasting; so, the KD relies an exogenous rather than body fat for ketone production, thus maintaining ketosis without weight loss. As the developing br
-
Acarbose and voglibose the classic glucosidase inhibitors we
2021-11-17
Acarbose and voglibose, the classic α-glucosidase inhibitors, were clinically used to inhibit α-glucosidase activity for the treatment of type 2 diabetes. However, the intake of these drugs may cause some undesirable gastrointestinal side effects and weight gain (Xu et al., 2015). The synthetic drug
-
Unlike our present results in
2021-11-17
Unlike our present results in 4–12-week-old (~1–3 months) females, where a high-fat-diet-induced increase in body weight was evident, Schmidt et al. exposed male glut3 mice to a similar high-fat diet (60% kilocalories from fat) and observed no change in body weight, plasma glucose or insulin concent
-
The effect of the selected compounds on NF kB
2021-11-17
The effect of the selected compounds on NF-kB transrepression was assessed using the well-studied HeLa B2 cell line that expresses endogenous GR and NF-kB family members and responds properly to glucocorticoids and pro-inflammatory cytokines (such as TNF). Our data revealed that the two hit compound
-
Receptors for glucagon Gcgr GLP Glp r
2021-11-17
Receptors for glucagon (Gcgr), GLP-1 (Glp1r), and GLP-2 (Glp2r) are G-protein coupled receptors (GPCRs) belonging to class B-1 (secretin receptor-like) family of GPCRs (Harmar, 2001, Fredriksson et al., 2003). The mammalian Gcgr, Glp1r, and Glp2r genes, together with the Vinpocetine australia for t
-
br Conflict of interest br
2021-11-17
Conflict of interest Transparency document Acknowledgements We acknowledge our funding sources from the American Heart Association (13EIA4480016) and the National Institute of Health/National Heart, Lung, and Blood Institute (RO1 HL094414). We are very grateful to Dr. Shaohua Xiao and Dr. S
-
Lapatinib Ditosylate Although domain organization had been c
2021-11-17
Although domain organization had been clearly delineated by the 4.3-Å structure of T4-γ-secretase [], atomic modeling of the side chains had to wait for the 3.4-Å structure []. In total, 598 residues in the transmembrane region and 632 residues in the ECD were modeled for the four components of huma
16423 records 569/1095 page Previous Next First page 上5页 566567568569570 下5页 Last page